Tardive dyskinesia: Diagnosis, pathogenesis, and management

Neurologist

Volumn 4, Issue 4, 1998, Pages 180-187

  Trugman, Joel M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Akathisia; Diagnosis; Dystonia; Pathogenesis; Tardive dyskinesia; Treatment

Indexed keywords

ALPHA TOCOPHEROL; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; PROLACTIN; PROPRANOLOL; QUETIAPINE; RESERPINE; RISPERIDONE; SERTINDOLE; TETRABENAZINE; TRIHEXYPHENIDYL;

AKATHISIA; BASAL GANGLION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INCIDENCE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0031872024     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00127893-199807000-00002     Document Type: Review

References (80)

1. American Psychiatric Association. Tardive dyskinesia: A task force report. Washington, DC: American Psychiatric Association, 1992.
2. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-7.
3. Bergen JA, Eyland EA, Campbell JA, Jenkings P, Kellehear K, Richards A, et al. The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 1989;154:523-8.
4. Burke RE. Neuroleptic-induced tardive dyskinesia variants. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. Mt. Kisco, NY: Futura, 1992:167-98.
5. Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: A study of 125 patients. South Med J 1990;83:525-32.
6. Chouza C, Scaramelli A, Caamano JL, De Medina O, Aljanati R, Romero S. Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine. Lancet 1986;1:1303-4.
7. Micheli F, Pardal MF, Gatto M, Torres M, Paradiso G, Parera IC, et al. Flunarizine- and cinnarizine-induced extrapyramidal reactions. Neurology 1987;37:881-4.
8. Lieberman JA, Flesichhacker WW. Introduction: Current issues in the development of atypical antipsychotic drugs. Br J Psychiatry 1996;168(29 Suppl):7-8.
9. Casey DE. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology Suppl 1989;99:S47-S53.
10. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57(Suppl 11):40-5.
11. Casey DE. Extrapyramidal syndromes and new antipsychotic drugs: Findings in patients and non-human primate models. Br J Psychiatry 1996;168(Suppl 29):32-9.
12. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54: 327-30.
13. Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone. J Clin Psychopharmacol 1997;17:308-13.
14. Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and Parkinsonism. Mov Disord 1997;12:119-21.
15. Woerner MG, Sheitman BB, Lieberman JA, Kane JM. Tardive dyskinesia induced by risperidone? [letter]. Am J Psychiatry 1996;153: 843.
16. Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58(Suppl 10):13-7.
17. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo - Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-57.
18. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154:782-91.
19. Wolf MA, Yassa R, Llorca PM. Neuroleptic-induced movement disorders: Historical perspective. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. New York: Cambridge University Press, 1997:3-9.
20. Fahn S. A therapeutic approach to tardive dyskinesia. J Clin Psychiatry 1985;46:19-24.
21. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995;18:197-214.
22. Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32:1335-46.
23. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986;1:193-208.
24. Wojcik JD, Falk WE, Fink JS, Cole JO, Gelenberg AJ. A review of 32 cases of tardive dystonia. Am J Psychiatry 1991;148:1055-9.
25. Sachdev P. Clinical characteristics of 15 patients with tardive dystonia. Am J Psychiatry 1993;150:498-500.
26. FitzGerald PM, Jankovic J. Tardive oculogyric crises. Neurology 1989;39:1434-7.
27. Friedman JH, Kucharski LT, Wagner RL. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry 1987;50:801-3.
28. Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985;42:874-8.
29. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: An analysis of clinical features and response to open therapeutic trials. Mov Disord 1989;4:157-75.
30. Sachdev P. Research diagnostic criteria for drug-induced akathisia: Conceptualization, rationale and proposal. Psychopharmacology 1994; 114:181-6.
31. Burke RE. Tardive akathisia. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. New York: Cambridge University Press, 1997:409-24.
32. Klawans HL, Falk DK, Nausieda PA, Weiner WJ. Gilles de la Tourette syndrome after long-term chlorpromazine therapy. Neurology 1978;28:1064-8.
33. Bharucha KJ, Sethi KD. Tardive tourettism after exposure to neuroleptic therapy. Mov Disord 1995;10:791-3.
34. Little JT, Jankovic J. Tardive myoclonus. Mov Disord 1987;2:307-11.
35. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(Suppl 4):1-63.
36. Yassa R, Nair NP, Iskander H, Schwartz G. Factors in the development of severe forms of tardive dyskinesia. Am J Psychiatry 1990;147:1156-63.
37. Kruk J, Sachdev P, Singh S. Neuroleptic-induced respiratory dyskinesia. J Neuropsychiatry Clin Neurosci 1995;7:223-9.
38. Ananth J, Swartz R, Chung C, Gadasally R. Dysarthria: Lonely symptom of tardive dystonia. Can J Psychiatry 1997;42:428-9.
39. Ford B, Greene P, Fahn S. Oral and genital tardive pain syndromes. Neurology 1994;44:2215-9.
40. Sachdev P. Risk factors for tardive dystonia: A case-control comparison with tardive dyskinesia. Acta Psychiatr Scand 1993;88:98-103.
41. Woerner MG, Kane JM, Liebemian JA, Alvir J, Bergmann KJ, Borenstein M, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991;11:34-42.
42. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: Prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8(Suppl 4): 52-6.
43. Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, Mayerhoff D, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996;53:313-9.
44. Morgenstern H, Glazer W. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained on neuroleptic medications: Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993;50:723-33.
45. Glazer WM, Morgenstern H, Wagner DR, Doucette J. The Yale tardive dyskinesia incidence study among long-term outpatients. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. New York: Cambridge University Press, 1997:41-55.
46. Saltz BL, Woerner MG, Kane JM, Leiberman JA, Alvir JMJ, Bergmann KJ, et al. Prospective study of tardive dyskinesia in the elderly. JAMA 1991;266:2402-6.
47. Gardos G, Casey DE, Cole HO, Perenyi A, Kocsis E, Arato M. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994;151: 836-41.
48. 2 antagonism in extrapyramidal functions. Br J Psychiatry 1992;160(Suppl 17):34-7.
49. 2 imbalance. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. New York: Cambridge University Press, 1997:141-60.
50. Trugman JM, Leadbetter R, Zalis ME, Burgdorf RO, Wooten GF. Treatment of severe axial tardive dystonia with clozapine: Case report and hypothesis. Mov Disord 1994;9:441-6.
51. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
52. 2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-9.
53. 2 and 5-HTs receptor occupancy studies and clinical response. Br J Psychiatry 1996;168(Suppl 29):40-4.
54. Gerfen CR. The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 1992;15:285-320.
55. 2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci 1995;15:5222-37.
56. 2 dopaminergic regulation of striatal preproenkephalin mRNA levels is mediated at least in part through cholinergic intemeurons. Brain Res Mol Brain Res 1992;13:35-41.
57. 1, dopamine receptor antagonists increases glucose utilization in the rat globus pallidus [abstract]. Soc Neurosci Abstr 1993;19:130.
58. 5-enkephalin-like immunoreactivity in rats following chronic treatment with haloperidol but not with clozapine: Implications for the pathogenesis of neuroleptic-induced movement disorders. Exp Neurol 1992;117:17-27.
59. 2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience 1992;49:285-96.
60. 1 stimulation. Life Sci 1983;33:2479-82.
61. 2 agonists LY171555 on oral movements in rats. Psychopharmacology 1988;96:253-7.
62. 2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur J Pharmacol 1990;186:49-59.
63. 1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats. J Neurosci 1989;9:125-33.
64. Casey DE. Neuroleptic-induced acute dystonia. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. Mt. Kisco, NY: Futura, 1992:21-40.
65. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: Factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8(Suppl 4): 21-6.
66. Meldrum BS, Anlezark GM, Marsden CD. Acute dystonia as an idiosyncratic response to neuroleptics in baboons. Brain 1977;100:313-26.
67. 1 receptor antagonists in schizophrenia. Psychopharmacology 1995;121:287-8.
68. Cassady SL, Thaker GK, Tamminga CA. GABAergic treatments for tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. New York: Cambridge University Press, 1997:454-69.
69. Richelson E. Preclinical pharmacology of neuroleptics: Focus on new generation compounds. J Clin Psychiatry 1996;57(Suppl 11):4-11.
70. Klawans HL, Tanner CM, Barr A. The reversibility of "permanent" tardive dyskinesia. Clin Neuropharmacol 1984;7:153-9.
71. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158:503-10.
72. Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics: A retro- and prospective study of extrapyramidal side effects. Psychopharmacology 1996;124:188-96.
73. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58:318-22.
74. Meltzer HY, Luchins DJ. Effect of clozapine in severe tardive dyskinesia: A case report. J Clin Psychopharmacol 1984;4:286-7.
75. Lamberti JS, Bellnier T. Clozapine and tardive dystonia. J Nerv Ment Disord 1993;181:137-8.
76. Shapleske J, McKay AP, McKenna PJ. Successful treatment of tardive dystonia with clozapine and clonazepam. Br J Psychiatry 1996;168: 516-8.
77. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-62.
78. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy. Am J Psychiatry 1990;147:445-51.
79. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996;57: 167-73.
80. Tarsy D, Kaufman D, Sethi KD, Rivner MH, Molho E, Factor S. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997;20:90-3.